Paper Details

  1. Home
  2. Paper Details

Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group.

Author: OmataM, SatomuraY, TakanoS

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study investigated the effectiveness of interferon in preventing non-A, non-B hepatitis from becoming chronic and determining the best treatment approach. Non-A, non-B hepatitis is more likely to become chronic and lead to liver cancer.
Paper Details　
Original Abstract of the Article :
Non-A, non-B acute hepatitis progresses to a higher incidence of chronicity and hepatocellular carcinoma. To avoid the development of chronic liver disease, resolution of acute hepatitis C might be most effective. The aim was to establish the effect of interferon in disturbing progression to chronic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0016-5085(94)90130-9

データ提供：米国国立医学図書館（NLM）

Interferon Beta: A Promising Treatment for Non-A, Non-B Acute Hepatitis

This prospective, randomized, controlled-dose study delves into the field of hepatology, specifically investigating the effectiveness of interferon beta in treating non-A, non-B acute hepatitis. The researchers aimed to evaluate the impact of interferon beta on the progression to chronicity and the development of hepatocellular carcinoma in patients with non-A, non-B acute hepatitis. They found that interferon beta demonstrated a positive effect in reducing the progression to chronic liver disease, suggesting that it could be a valuable treatment option for this condition.

A Potential Treatment for Chronic Liver Disease

This study provides evidence that interferon beta could be a valuable treatment for non-A, non-B acute hepatitis, potentially reducing the progression to chronic liver disease. This is a significant finding, as chronic hepatitis can lead to serious complications, including liver failure and cancer. The study's results warrant further investigation into the long-term benefits and optimal dosage of interferon beta for treating this condition.

Hope for Non-A, Non-B Hepatitis Patients

This research offers hope for individuals diagnosed with non-A, non-B hepatitis. The study's findings suggest that interferon beta could play a crucial role in managing this condition, reducing the risk of developing chronic liver disease. However, further research is needed to confirm the long-term efficacy and safety of this treatment approach.

Dr.Camel's Conclusion

Just as a camel can navigate the unforgiving desert terrain with its innate abilities, interferon beta seems to offer a potential path for navigating the challenges of non-A, non-B acute hepatitis. It's a reminder that even in the face of complex medical conditions, researchers are constantly seeking new solutions and innovations to improve patient outcomes. This study offers a glimmer of hope for individuals with non-A, non-B hepatitis, suggesting that there may be a way to manage this condition and reduce the risk of developing chronic liver disease.

Date :
  1. Date Completed 1994-09-30
  2. Date Revised 2019-07-07
Further Info :

Pubmed ID

8076768

DOI: Digital Object Identifier

10.1016/0016-5085(94)90130-9

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.